Wilding, John P.H.

Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study

Heerspink, H. J. L., Karasik, A., Thuresson, M., Melzer-Cohen, C., Chodick, G., Khunti, K., Wilding, J. P. H., Garcia Rodriguez, L. A., Cea-Soriano, L., Kohsaka, S., et al. (2020) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 317

The importance of weight management in type 2 diabetes mellitus

Wilding, J. P. H. (2014) · International Journal of Clinical Practice

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 314

Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5

Kushner, R. F., Calanna, S., Davies, M., Dicker, D., Garvey, W. T., Goldman, B., Lingvay, I., Thomsen, M., Wadden, T. A., Wharton, S., et al. (2020) · Obesity

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 288

Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial

Colhoun, H. M., Lingvay, I., Brown, P. M., Deanfield, J., Brown-Frandsen, K., Kahn, S. E., Plutzky, J., Node, K., Parkhomenko, A., Rydén, L., et al. (2024) · Nature Medicine

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 238

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.

Garvey, W. T., Blüher, M., Osorto Contreras, C. K., Davies, M. J., Winning Lehmann, E., Pietiläinen, K. H., Rubino, D., Sbraccia, P., Wadden, T., Zeuthen, N., et al. (2025) · New England Journal of Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 238

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects

for the OBES-002 Study Group, Wilding, J., Gaal, L. V., Rissanen, A., Vercruysse, F., & Fitchet, M. (2004) · International Journal of Obesity

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 224

New insights into the treatment of obesity

Blüher, M., Aras, M., Aronne, L. J., Batterham, R. L., Giorgino, F., Ji, L., Pietiläinen, K. H., Schnell, O., Tonchevska, E., & Wilding, J. P. H. (2023) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 158

Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials

Ahrén, B., Atkin, S. L., Charpentier, G., Warren, M. L., Wilding, J. P. H., Birch, S., Holst, A. G., & Leiter, L. A. (2018) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 157

Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus

Berg, D. D., Wiviott, S. D., Scirica, B. M., Gurmu, Y., Mosenzon, O., Murphy, S. A., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., et al. (2019) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 154

Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo‐controlled trial

Zelissen, P. M. J., Stenlof, K., Lean, M. E. J., Fogteloo, J., Keulen, E. T. P., Wilding, J., Finer, N., Rössner, S., Lawrence, E., Fletcher, C., et al. (2005) · Diabetes, Obesity and Metabolism

Regulation of Appetite and ObesityPharmacology and Obesity Treatment

Cited by 144

An audit of 500 subcutaneous glucagon stimulation tests to assess growth hormone and ACTH secretion in patients with hypothalamic-pituitary disease

Leong, K. S., Walker, A. B., Martin, I., Wile, D., Wilding, J., & MacFarlane, I. A. (2001) · Clinical Endocrinology

Pituitary Gland Disorders and TreatmentsAdrenal Hormones and Disorders

Cited by 140

Short-term decreased physical activity with increased sedentary behaviour causes metabolic derangements and altered body composition: effects in individuals with and without a first-degree relative with type 2 diabetes

Bowden Davies, K. A., Sprung, V. S., Norman, J. A., Thompson, A., Mitchell, K. L., Halford, J. C. G., Harrold, J. A., Wilding, J. P. H., Kemp, G. J., & Cuthbertson, D. J. (2018) · Diabetologia

Physical Activity and HealthAdipokines, Inflammation, and Metabolic Diseases

Cited by 138

Cardiac Autonomic Neuropathy in Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review

Williams, S. M., Eleftheriadou, A., Alam, U., Cuthbertson, D. J., & Wilding, J. P. H. (2019) · Diabetes Therapy

Heart Rate Variability and Autonomic ControlDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 128

Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials

O'Neil, P. M., Aroda, V. R., Astrup, A., Kushner, R., Lau, D. C. W., Wadden, T. A., Brett, J., Cancino, A., Wilding, J. P. H., & groups, O. B. O. T. S. A. C. A. –. L. E. I. I. W. A. W. D. (. S. (2017) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 115

The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58

Mosenzon, O., Wiviott, S. D., Heerspink, H. J. L., Dwyer, J. P., Cahn, A., Goodrich, E. L., Rozenberg, A., Schechter, M., Yanuv, I., Murphy, S. A., et al. (2021) · Diabetes Care

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 113

Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study

Wilding, J. P. H., Batterham, R. L., Calanna, S., Van Gaal, L. F., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wharton, S., Yokote, K., Zeuthen, N., et al. (2021) · Journal of the Endocrine Society

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 107

Exposure-response analyses of liraglutide 3.0 mg for weight management

Wilding, J. P. H., Overgaard, R. V., Jacobsen, L. V., Jensen, C. B., & le Roux, C. W. (2016) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 102

Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program

Perreault, L., Davies, M., Frias, J. P., Laursen, P. N., Lingvay, I., Machineni, S., Varbo, A., Wilding, J. P. H., Wallenstein, S. O. R., & le Roux, C. W. (2022) · Diabetes Care

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 87

The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD)

Thondam, S. K., Cuthbertson, D. J., & Wilding, J. P. H. (2020) · Peptides

Adipokines, Inflammation, and Metabolic DiseasesRegulation of Appetite and Obesity

Cited by 77

Cardiovascular outcome trials in obesity: A review

Wilding, J. P. H., & Jacob, S. (2021) · Obesity Reviews

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 75

Risk of diabetic retinopathy and diabetic macular oedema with sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database

Eleftheriadou, A., Riley, D., Zhao, S. S., Austin, P., Hernández, G., Lip, G. Y. H., Jackson, T. L., Wilding, J. P. H., & Alam, U. (2024) · Diabetologia

Diabetes Treatment and ManagementRetinal Diseases and Treatments

Cited by 73

Early findings from the NHS Type 2 Diabetes Path to Remission Programme: a prospective evaluation of real-world implementation

Valabhji, J., Gorton, T., Barron, E., Safazadeh, S., Earnshaw, F., Helm, C., Virr, M., Kernan, J., Crowe, S., Aveyard, P., et al. (2024) · The Lancet Diabetes & Endocrinology

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 72

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events

Lingvay, I., Hansen, T., Macura, S., Marre, M., Nauck, M. A., de la Rosa, R., Woo, V., Yildirim, E., & Wilding, J. (2020) · BMJ Open Diabetes Research & Care

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 71

Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response

Thondam, S. K., Daousi, C., Wilding, J. P. H., Holst, J. J., Ameen, G. I., Yang, C., Whitmore, C., Mora, S., & Cuthbertson, D. J. (2017) · American Journal of Physiology-Endocrinology and Metabolism

Adipokines, Inflammation, and Metabolic DiseasesAdipose Tissue and Metabolism

Cited by 71